Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Yoshihiro Umezawa"'
Autor:
Megumi Akiyama, Masashi Kanayama, Yoshihiro Umezawa, Toshikage Nagao, Yuta Izumi, Masahide Yamamoto, Toshiaki Ohteki
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Innate immune cells play a key role in inflammation as a source of pro-inflammatory cytokines. However, it remains unclear how innate immunity-mediated inflammation is fine-tuned to minimize tissue damage and assure the host’s survival at the early
Externí odkaz:
https://doaj.org/article/58dce29f44d34dada377f630ef1cf21c
Autor:
Yotaro Motomura, Yoshihiro Umezawa, Tomoyuki Arimatsu, Keigo Okada, Osamu Miura, Takashi Kumagai
Publikováno v:
Clinical Case Reports, Vol 10, Iss 2, Pp n/a-n/a (2022)
Abstract We report a case of fever of unknown origin in a patient with MDS associated with IgM‐MGUS. The patient was positive for MYD88 mutation, and chemotherapy for LPL/WM improved the fever. Analysis of MYD88 and the effect of chemotherapy on LP
Externí odkaz:
https://doaj.org/article/b2245996496b498fae4921a182f63970
Publikováno v:
Translational Oncology, Vol 12, Iss 2, Pp 336-349 (2019)
FLT3-ITD and FLT3-TKD are the most frequent tyrosine kinase mutations in acute myeloid leukemia (AML), with the former conferring a poor prognosis. We have recently revealed that FLT3-ITD confers resistance to the PI3K/AKT pathway inhibitors by prote
Externí odkaz:
https://doaj.org/article/fe836c00a4bc4fe7a6f6be7ebf44d7fd
Autor:
Aya Usami, Kota Yokoyama, Junichi Tsuchiya, Yoshihiro Umezawa, Kazuma Toda, Ukihide Tateishi, Ryoichi Yoshimura
Publikováno v:
Diagnostics, Vol 12, Iss 2, p 504 (2022)
A 44-year-old woman presented with high [18F]FDG uptake liver lesion after six courses of R-CHOP and radiotherapy for abdominal DLBCL, which was misdiagnosed as a hepatic invasion. EOB–MRI showed slight T2 hyperintensity, low-intensity DWI, and dec
Externí odkaz:
https://doaj.org/article/472244be3520464887147fb9ba9dadaf
Autor:
Toshikage Nagao, Tetsuya Kurosu, Yoshihiro Umezawa, Ayako Nogami, Gaku Oshikawa, Shuji Tohda, Masahide Yamamoto, Osamu Miura
Publikováno v:
PLoS ONE, Vol 9, Iss 1, p e84746 (2014)
The gain of function mutation JAK2-V617F is very frequently found in myeloproliferative neoplasms (MPNs) and is strongly implicated in pathogenesis of these and other hematological malignancies. Here we report establishment of a new leukemia cell lin
Externí odkaz:
https://doaj.org/article/e8bd8ba7c170486980f07e8854dcb8cc
Autor:
Yoshihiro Umezawa, Koji Sasaki
Publikováno v:
International Journal of Hematology. 117:24-29
The therapeutic outcomes of chronic myeloid leukemia (CML) have improved dramatically since tyrosine kinase inhibitors (TKIs) became available in clinical practice. Life expectancy of patients with CML is now close to that of the general population.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4fa2ae0b40c8e41c1cba9e2d5b3467c
https://doi.org/10.1007/s12185-022-03431-8
https://doi.org/10.1007/s12185-022-03431-8
Autor:
Asuka Kono, Manabu Wakamatsu, Yoshihiro Umezawa, Hideki Muramatsu, Hiroki Fujiwara, Dan Tomomasa, Kento Inoue, Keiichiro Hattori, Tetsuo Mitsui, Hidetoshi Takada, Yoshiyuki Minegishi, Yoshiyuki Takahashi, Masahide Yamamoto, Takehiko Mori, Hirokazu Kanegane
Publikováno v:
International Journal of Hematology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b64146d89f183a50ca22cbed96f0360
https://doi.org/10.1007/s12185-023-03613-y
https://doi.org/10.1007/s12185-023-03613-y
Risk factors for CAR‐T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan
Autor:
Tomoyasu Jo, Satoshi Yoshihara, Yoshiki Okuyama, Keiko Fujii, Tomoko Henzan, Kaoru Kahata, Rie Yamazaki, Wataru Takeda, Yoshihiro Umezawa, Kentaro Fukushima, Takashi Ashida, Minami Yamada‐Fujiwara, Ryo Hanajiri, Noboru Yonetani, Yuma Tada, Yuji Shimura, Hidekazu Nishikii, Norio Shiba, Naoya Mimura, Jun Ando, Takayuki Sato, Yasuhiro Nakashima, Junko Ikemoto, Keita Iwaki, Shin‐ichiro Fujiwara, Masaki Ri, Tokiko Nagamura‐Inoue, Ryuji Tanosaki, Yasuyuki Arai
Publikováno v:
British Journal of Haematology.
For successful chimeric antigen receptor T (CAR-T) cell therapy, CAR-T cells must be manufactured without failure caused by suboptimal expansion. In order to determine risk factors for CAR-T cell manufacturing failure, we performed a nationwide cohor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4510dea0235b034671841fcea67d60e4
https://doi.org/10.1111/bjh.18831
https://doi.org/10.1111/bjh.18831
Autor:
Mai Kuboki, Yotaro Motomura, Toshikage Nagao, Ayako Nogami, Keigo Okada, Masahide Yamamoto, Yoshihiro Umezawa, Osamu Miura
Publikováno v:
In Vivo
Background Neurotoxicity is one of the dangerous complications of chimeric antigen receptor (CAR) T-cell therapy, while its pathophysiology remains to be fully understood. Motor weakness not associated with central nervous system (CNS) toxicity has r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca7872cd811b6fafda92143f2b1685ec
https://doi.org/10.21873/invivo.12640
https://doi.org/10.21873/invivo.12640
Autor:
Moyu, Kimura, Yu, Nishiyama, Hiroki, Ueda, Akiko, Kitajo, Tomoyuki, Arimatsu, Mai, Kuboki, Atsushi, Takahata, Makiko, Saito, Chizuko, Sakashita, Keigo, Okada, Yoshihiro, Umezawa, Toshikage, Nagao, Masahide, Yamamoto, Shuji, Tohda, Minoru, Tanabe, Takehiko, Mori, Ayako, Nogami
Publikováno v:
[Rinsho ketsueki] The Japanese journal of clinical hematology. 63(4)
Paroxysmal nocturnal hemoglobinuria (PNH) is characterized by hemolysis, thrombosis, and bone marrow failure. Infection, pregnancy, and surgical operation have the potential to evoke severe episodes of hemolysis and thrombosis. Therefore, the use of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::857002c47f376082a645fe3e8097311f
https://pubmed.ncbi.nlm.nih.gov/35491214
https://pubmed.ncbi.nlm.nih.gov/35491214